ME02841B - Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze - Google Patents
Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferazeInfo
- Publication number
- ME02841B ME02841B MEP-2017-224A MEP2017224A ME02841B ME 02841 B ME02841 B ME 02841B ME P2017224 A MEP2017224 A ME P2017224A ME 02841 B ME02841 B ME 02841B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- hemmer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Spoj, naznačen time što je spoj formule , ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule , ili njegova farmaceutski prihvatljiva sol.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što je spoj formule .
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegovu farmaceutski prihvatljivu sol, kao i jednu ili više farmaceutski prihvatljivih podloga, razrjeđivača ili pomoćnih tvari.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što sadrži jedno ili više drugih terapijskih sredstava.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u smanjivanju povećanja težine.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u smanjivanju ponovnog povećanja težine.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju pretilosti.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju dijabetesa tip 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382460 | 2013-11-14 | ||
| EP14802755.0A EP3068775B1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
| PCT/US2014/064202 WO2015073281A1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02841B true ME02841B (me) | 2018-01-20 |
Family
ID=49622771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-224A ME02841B (me) | 2013-11-14 | 2014-11-06 | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9035051B1 (me) |
| EP (1) | EP3068775B1 (me) |
| JP (1) | JP6159484B2 (me) |
| KR (1) | KR101739243B1 (me) |
| CN (1) | CN105636948B (me) |
| AP (1) | AP2016009189A0 (me) |
| AR (1) | AR098274A1 (me) |
| AU (1) | AU2014348967B2 (me) |
| BR (1) | BR112016009488B1 (me) |
| CA (1) | CA2926224C (me) |
| CL (1) | CL2016001023A1 (me) |
| CR (1) | CR20160184A (me) |
| CY (1) | CY1119489T1 (me) |
| DK (1) | DK3068775T3 (me) |
| DO (1) | DOP2016000070A (me) |
| EA (1) | EA028550B1 (me) |
| ES (1) | ES2647790T3 (me) |
| HR (1) | HRP20171648T1 (me) |
| HU (1) | HUE035590T2 (me) |
| IL (1) | IL244856A (me) |
| JO (1) | JO3302B1 (me) |
| LT (1) | LT3068775T (me) |
| MA (1) | MA39025B1 (me) |
| ME (1) | ME02841B (me) |
| MX (1) | MX2016006223A (me) |
| NO (1) | NO3068775T3 (me) |
| NZ (1) | NZ718373A (me) |
| PE (1) | PE20160609A1 (me) |
| PH (1) | PH12016500895A1 (me) |
| PL (1) | PL3068775T3 (me) |
| PT (1) | PT3068775T (me) |
| RS (1) | RS56533B1 (me) |
| SG (1) | SG11201602953YA (me) |
| SI (1) | SI3068775T1 (me) |
| TN (1) | TN2016000145A1 (me) |
| TW (1) | TWI538677B (me) |
| UA (1) | UA118034C2 (me) |
| WO (1) | WO2015073281A1 (me) |
| ZA (1) | ZA201602202B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104672A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| MA45843B1 (fr) | 2016-08-05 | 2021-06-30 | Boehringer Ingelheim Int | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
| CN106478519B (zh) * | 2016-10-10 | 2018-12-11 | 上海再启生物技术有限公司 | 一种2-甲基-4-氨基-6-氯嘧啶的制备方法 |
| CN111655700B (zh) | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| JP7083397B2 (ja) * | 2018-02-02 | 2022-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体 |
| JP7150032B2 (ja) * | 2018-02-02 | 2022-10-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体 |
| CN108774221A (zh) * | 2018-05-30 | 2018-11-09 | 王丽萍 | 一种goat抑制剂及其在肥胖和糖尿病中的应用 |
| CN108558849A (zh) * | 2018-05-30 | 2018-09-21 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| CN108516971A (zh) * | 2018-05-30 | 2018-09-11 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| CN108558852A (zh) * | 2018-05-30 | 2018-09-21 | 王丽萍 | 一种goat抑制剂及其在肥胖和糖尿病中的应用 |
| CN108610337A (zh) * | 2018-05-30 | 2018-10-02 | 王丽萍 | 一种苯并[b]噻吩类化合物及其在肥胖和糖尿病中的应用 |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| CN115916789B (zh) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| ES2984466T3 (es) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003528088A (ja) * | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| WO2005026211A2 (en) | 2003-09-05 | 2005-03-24 | Eli Lilly And Company | Anti-ghrelin antibodies |
| JP2008515771A (ja) | 2004-07-14 | 2008-05-15 | イーライ リリー アンド カンパニー | 抗グレリン抗体 |
| CA2587627A1 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
| US7479271B2 (en) | 2005-02-23 | 2009-01-20 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
| CN101175759A (zh) * | 2005-05-17 | 2008-05-07 | 先灵公司 | 作为治疗血脂异常的烟酸受体激动剂的杂环化合物 |
| JP4975739B2 (ja) * | 2005-05-17 | 2012-07-11 | シェーリング コーポレイション | 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環 |
| WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| RU2010142937A (ru) * | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ |
| AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
-
2014
- 2014-06-11 UA UAA201604765A patent/UA118034C2/uk unknown
- 2014-10-30 JO JOP/2014/0316A patent/JO3302B1/ar active
- 2014-10-31 TW TW103137938A patent/TWI538677B/zh active
- 2014-11-03 AR ARP140104111A patent/AR098274A1/es unknown
- 2014-11-06 BR BR112016009488-3A patent/BR112016009488B1/pt active IP Right Grant
- 2014-11-06 MX MX2016006223A patent/MX2016006223A/es active IP Right Grant
- 2014-11-06 AU AU2014348967A patent/AU2014348967B2/en active Active
- 2014-11-06 SG SG11201602953YA patent/SG11201602953YA/en unknown
- 2014-11-06 CN CN201480058584.6A patent/CN105636948B/zh active Active
- 2014-11-06 PL PL14802755T patent/PL3068775T3/pl unknown
- 2014-11-06 CA CA2926224A patent/CA2926224C/en active Active
- 2014-11-06 TN TN2016000145A patent/TN2016000145A1/en unknown
- 2014-11-06 LT LTEP14802755.0T patent/LT3068775T/lt unknown
- 2014-11-06 HR HRP20171648TT patent/HRP20171648T1/hr unknown
- 2014-11-06 HU HUE14802755A patent/HUE035590T2/en unknown
- 2014-11-06 SI SI201430379T patent/SI3068775T1/sl unknown
- 2014-11-06 JP JP2016531705A patent/JP6159484B2/ja active Active
- 2014-11-06 ME MEP-2017-224A patent/ME02841B/me unknown
- 2014-11-06 RS RS20171067A patent/RS56533B1/sr unknown
- 2014-11-06 PT PT148027550T patent/PT3068775T/pt unknown
- 2014-11-06 PE PE2016000620A patent/PE20160609A1/es active IP Right Grant
- 2014-11-06 EA EA201690764A patent/EA028550B1/ru not_active IP Right Cessation
- 2014-11-06 AP AP2016009189A patent/AP2016009189A0/en unknown
- 2014-11-06 DK DK14802755.0T patent/DK3068775T3/en active
- 2014-11-06 WO PCT/US2014/064202 patent/WO2015073281A1/en not_active Ceased
- 2014-11-06 MA MA39025A patent/MA39025B1/fr unknown
- 2014-11-06 KR KR1020167012340A patent/KR101739243B1/ko active Active
- 2014-11-06 NO NO14802755A patent/NO3068775T3/no unknown
- 2014-11-06 ES ES14802755.0T patent/ES2647790T3/es active Active
- 2014-11-06 US US14/534,212 patent/US9035051B1/en active Active
- 2014-11-06 NZ NZ718373A patent/NZ718373A/en unknown
- 2014-11-06 EP EP14802755.0A patent/EP3068775B1/en active Active
-
2016
- 2016-03-29 DO DO2016000070A patent/DOP2016000070A/es unknown
- 2016-04-03 IL IL244856A patent/IL244856A/en active IP Right Grant
- 2016-04-04 ZA ZA201602202A patent/ZA201602202B/en unknown
- 2016-04-21 CR CR20160184A patent/CR20160184A/es unknown
- 2016-04-29 CL CL2016001023A patent/CL2016001023A1/es unknown
- 2016-05-13 PH PH12016500895A patent/PH12016500895A1/en unknown
-
2017
- 2017-10-20 CY CY20171101093T patent/CY1119489T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02841B (me) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| HRP20171512T1 (hr) | Derivati betulina | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MD4736B1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| PH12015501993B1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| EP3071280A4 (en) | TREATMENT CATHETER WITH THERAPEUTIC ENERGY SUPPLY | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| HRP20191523T1 (hr) | Paraziticidne kombinacije spirocikličkog izoksazolina | |
| ME02840B (me) | Spojevi fenoksietilpiperidina | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| ME02404B (me) | Tetrahidropirolotiazinski spojevi | |
| JP2015516419A5 (me) | ||
| EA201692298A1 (ru) | Производные карбоксамидов | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |